The 48 references in paper D. Kalimullina Kh., A. Yurkina S., T. Ushakova I., D. Blinov V., Д. Калимуллина Х., А. Юркина С., Т. Ушакова И., Д. Блинов В. (2017) “Распространенность неалкогольной жировой болезни печени в Республике Башкортостан (региональные результаты исследования DIREG 2) // PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN REPUBLIC OF BASHKORTOSTAN (REGIONAL RESULTS OF DIREG 2 STUDY)” / spz:neicon:pharmacoeconomics:y:2016:i:4:p:14-23

1
Bokeriya L. A. i dr. Byulleten’ NTsSSKh im. AN Bakuleva RAMN.
(check this in PDF content)
2
07; 8 (5): 5-11. 2. Drapkina O. M., Korneeva O. N., Ivashkin V. T. Lechashchii vrach. 2010; 2: 43-45.
(check this in PDF content)
3
Drapkina O. M., Ivashkin V. T. RZhGGK. 2014; 4: 32-38.
(check this in PDF content)
4
Ivashkin V. T., Maevskaya M. V, Pavlov Ch. S., Shirokova E. N., Bueverov A. O., Drapkina O. M., Shul’pekova Yu. O., Tsukanov V. V., Mammaev S. N., Pal’gova L. K., Tikhonov I. N. Diagnosis and treatment of nonalcoholic fatty liver disease [Diagnostika i lechenie nealkogol’noi zhirovoi bolezni pecheni. Metodicheskie rekomendatsii dlya vrachei. ROPIP (in Russian)]. Moscow. 2015. URL: http://www.rsls.ru/files/ Guidelines-RSLS-NASH-2016-01-03.pdf. Accessed: 13.03.2016.
(check this in PDF content)
5
Ivashkin V. T., Maevskaya M. V. Ros zhurn gastroenterol gepatol koloproktol. 2010; 1: 4-13.
(check this in PDF content)
6
Ivashkin V. T. i soavt. Rossiiskie meditsinskie vesti. 2014; 4: 82-91.
(check this in PDF content)
7
Ivashkin V. T., Drapkina O. M., Maev I. V., Trukhmanov A. S., Blinov D. V., Pal’gova L. K., Tsukanov V. V., Ushakova T. I. RZhGGK. 2015; 6: 31-41.
(check this in PDF content)
8
Ignat’eva V. I., Avksent’eva M. V. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2014; 3: 3-11.
(check this in PDF content)
9
Korneeva O. N., Drapkina O. M. Ros. zhurn. gastroenterol., gepatol., koloproktol.. 2007; 1 (17): 65.
(check this in PDF content)
10
Lazebnik L. B., Zvenigorodskaya L. A. Metabolic syndrome and digestive organs [Metabolicheskii sindrom i organy pishchevareniya (in Russian)]. Moscow. 2009; 182 s.
(check this in PDF content)
11
Lipatova L. V. pilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 20-27.
(check this in PDF content)
12
Makarov I. O., Borovkova E. I., Kazakov R. D. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2012; 4: 18-21.
(check this in PDF content)
13
Makarov I. O., Pavlov Ch. S., Shemanaeva T. V., Voevodin S. M., Muravei A. Yu. Akusherstvo, ginekologiya i reproduktsiya / Obstetrics, gynecology and reproduction. 2013; 1: 22-25.
(check this in PDF content)
14
Mamedov M. N., Oganov R. G. Profilaktika zabolevanii i ukreplenie zdorov’ya. 2005; 8 (6): 41-45.
(check this in PDF content)
15
Odinak M. M., Bazilevich S. N., Dyskin D. E., Prokudin M. Yu. Epilepsiya i paroksizmal’nye sostoyaniya / Epilepsy and paroxysmal conditions. 2010; 3: 45-50.
(check this in PDF content)
16
Polivanov V. A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 7-11.
(check this in PDF content)
17
Tsukanov V. V., Tonkikh Yu. L., Kasparov E. V. et al. Vrach. 2010; 9: 1-4.
(check this in PDF content)
18
Shul’pekova Yu. O. Farmateka. 2007; 141 (6): 48-53.
(check this in PDF content)
19
Aithal G. P., Das K., Chowdhury A. Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD). GI Epidemiology: Diseases and Clinical Methodology, Second Edition. 2014; 357-372.
(check this in PDF content)
20
Alberti K. G., Zimmet P., Shaw J.; IDF Epidemiology Task Force Consensus Group. The metabolic syndrome – a new worldwide definition. Lancet. 2005; 366 (9491): 1059-1062.
(check this in PDF content)
21
Anfossi G., Massucco P., Bonomo K., Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr. Metab. Cardiovasc. Dis. 2004; 14: 215-224.
(check this in PDF content)
22
Argo S. K., Loria P., Caldwell S. H., Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008; 48 (2): 662-669.
(check this in PDF content)
23
Browning J. S., Szczepaniak L. S., Dobbings L. S., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004; 40 (7): 1387-95.
(check this in PDF content)
24
Brunt E. M. Nonalcoholic steatohepatiatis. Semin Liver Dis. 2004; 24: 3-20.
(check this in PDF content)
25
Clark J. M. The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 2006; 40: 5-10.
(check this in PDF content)
26
Alwis N. M., Day C. P. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008; 48 (1): 104-112.
(check this in PDF content)
27
Denus S., Spinier S. A., Miller K. Statins and liver toxicity: a meta-analysis. Pharmactiherapy. 2004; 24 (5): 584-591.
(check this in PDF content)
28
Drapkina O., Evsyutina Y., Ivashkin V. Prevalence of nonalcoholic fatty liver disease in the Russian Federation: the open, multicenter, prospective study, DIREG 1. American Journal of Clinical Medicine Research. 2015; 3 (2): 31-36. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2016; Том 9, No 4 www.pharmacoeconomics.ru Сведения об авторах: Калимуллина Дилара Хатимовна – главный внештатный специалист по клинической фармакологии Минздрава Республики Башкортостан. Институт дополнительного профессионального образования ФГБОУ ВПО «Башкирский государственный медицинский университет» Минздрава России. Адрес: ул. Ленина, 3, г. Уфа, Республика Башкортостан, 450000. Юркина А. С. – Федеральное государственное бюджетное образовательное учреждение высшего образования Первы
(check this in PDF content)
29
Drapkina O. M., Ivashkin V. T. Liver disease structure explored in Russian Federation: national-wide DIREG-L-01903 study for non-alcoholic fatty liver disease screening. Journal of Hepatology. 2011; 54: 332.
(check this in PDF content)
30
Forse R. A., Krishnamurty D. M. Epidemiology and Discrimination in Obesity. The ASMBS Textbook of Bariatric Surgery. Springer New York. 2015; 3-12.
(check this in PDF content)
31
Goland S. et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. Journal of clinical gastroenterology. 2006; 40 (10): 949-955.
(check this in PDF content)
32
Grundy S. M., Cleeman J. I., Daniels S. R. et al.; American Heart Association; National Heart, Lung, and Blood Institute (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association / National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 112 (17): 2735-2752.
(check this in PDF content)
33
Gundermann K. J., Kuenker A., Kuntz E., Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011; 63: 643-659.
(check this in PDF content)
34
Hamaguchi M., Kojima T., Takeda N. et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-84.
(check this in PDF content)
35
Haring R., Wallaschofski H., Nauck M., Dörr M., Baumeister S. E., Völzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl-transpeptidase levels. Hepatology. 2009; 50: 1403-11.
(check this in PDF content)
36
Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. United European Gastroenterology Journal. 2015; 3 (1): 344-345.
(check this in PDF content)
37
Ivashkin V. T., Drapkina O. M., Maev I. V., Troukhmanov A. S., Zimovina U. V., Palgova L. K., Blinov D. V., Shirokova E. N., Tsukanov V. V. Non-alcoholic fatty liver disease risk factors assessment among the general practitioners and gastroenterologist’s patients flow. UEG Week 2015. UEG15-ABS-3697.
(check this in PDF content)
38
Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011; 343: d6891.
(check this in PDF content)
39
Ludwig J., Viggiano T. R., McGill D. B., Oh B. J. Nonalcoholic steatohepati-tis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.
(check this in PDF content)
40
Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A. J., Natale S., Forlani G., Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50: 1844-50.
(check this in PDF content)
41
McCullough A. J. Epidemiology of the metabolic syndrome in the USA. Journal of digestive diseases. 2011; 12 (5): 333-340.
(check this in PDF content)
42
Neuschwander-Tetri B. A., Caldwell S. H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003; 37: 1202-19.
(check this in PDF content)
43
Nomura H., Kashiwaqi S., Hayashi J., et al. Prevalence of fatty liver in a general population of Okinawa Japan. Jap J Med. 1998; 27 (1): 142-9.
(check this in PDF content)
44
Picardi A., Vespasiani-Gentilucci U. Association between nonalcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol. 2008; 103: 3036-8.
(check this in PDF content)
45
Sanyal A. J., Banas C., Sargeant C., Luketic V. A., Sterling R. K., Stravitz R. T., et al. Similarities and differences in outcomes of cirrhosis due to non-alcoholic steatohepatitis and hepatitis C. Hepatology. 2006; 43: 682-689.
(check this in PDF content)
46
Schwimmer J. B. et al. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006; 118 (4): 1388-1393.
(check this in PDF content)
47
Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. Journal of hepatology. 2008; 49 (4): 600-607.
(check this in PDF content)
48
Targher G., Marra F., Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenome-non? Diabetologia. 2008; 51: 1947-1953.
(check this in PDF content)